Description

The global pharmacogenomics market is poised to grow by US$ 6.7 billion during 2022-2028, progressing at a CAGR of 10.5% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for pharmacogenomics. The global pharmacogenomics market is segmented on the basis of product, technology, application, end user, and region. By product, the global pharmacogenomics market has been segmented into consumables, instruments, software. Based upon technology, the global pharmacogenomics market is categorized into microarray, polymerase chain reaction (PCR), sequencing, others. On the basis of application, the global pharmacogenomics market has been segmented into cardiovascular diseases, neurology and psychiatry, oncology, respiratory and inflammatory diseases, others. By end user, the global pharmacogenomics market has been segmented into hospitals and clinics, independent testing laboratories, research institutions, others. Geographically, the global pharmacogenomics market is segmented into North America, Europe, Asia-Pacific, Rest of the World.

The global pharmacogenomics market is highly competitive. The pharmacogenomics market is dominated by key players, which are Abbott Laboratories, Agilent Technologies Inc, Becton Dickinson and Company, BGI Group Inc., Bio-Rad Laboratories Inc., Diatech Pharmacogenetics S.R.L., Dynamic DNA Laboratories, F. Hoffmann-La Roche AG, Illumina Inc, LGC Biosearch Technologies, Mesa Labs Inc. (Agena Bioscience Inc.), Myriad Genetics Inc, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Thermo Fisher Scientific Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the pharmacogenomics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: consumables, instruments, software
Technology: microarray, polymerase chain reaction (PCR), sequencing, others
Application: cardiovascular diseases, neurology and psychiatry, oncology, respiratory and inflammatory diseases, others
End user: hospitals and clinics, independent testing laboratories, research institutions, others
Region: North America, Europe, Asia-Pacific, Rest of the World
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global pharmacogenomics market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Pharmacogenomics market overview
Part 3. Market breakdown by product
– Consumables
– Instruments
– Software
Part 4. Market breakdown by technology
– Microarray
– Polymerase chain reaction (PCR)
– Sequencing
– Others
Part 5. Market breakdown by application
– Cardiovascular diseases
– Neurology and psychiatry
– Oncology
– Respiratory and inflammatory diseases
– Others
Part 6. Market breakdown by end user
– Hospitals and clinics
– Independent testing laboratories
– Research institutions
– Others
Part 7. Market breakdown by region
– North America
– Europe
– Asia-Pacific
– Rest of the World
Part 8. Key companies
– Abbott Laboratories
– Agilent Technologies, Inc
– Becton, Dickinson and Company
– BGI Group Inc.
– Bio-Rad Laboratories, Inc.
– Diatech Pharmacogenetics S.R.L.
– Dynamic DNA Laboratories
– F. Hoffmann-La Roche AG
– Illumina, Inc
– LGC Biosearch Technologies
– Mesa Labs, Inc. (Agena Bioscience, Inc.)
– Myriad Genetics, Inc
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, Inc.
– Qiagen N.V.
– Thermo Fisher Scientific Inc
About StrategyHelix
Disclaimer